Chapuis-Biron C, Bourrier A, Nachury M, et al. - Researchers performed a nationwide multicentre cohort study to evaluate the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort. Participants in the study were patients (n = 151) with perianal Crohn disease who received vedolizumab, the first biologic agent targeting specifically the mucosal integrin receptor. Data reported that 68% of patients stopped therapy after a median time of 33 weeks. In multivariable analysis, factors related to success were the number of prior biologic agents and no antibiotics at the initiation. For patients with active perianal Crohn disease, a low success rate of vedolizumab was identified, and approximately one-third of patients with inactive perianal Crohn disease had perianal recurrences.